The cell and gene therapy (CGT) contract manufacturing landscape has a new market entrant, and it’s a big one. On May 7, 2026, San Francisco-based private investment firm GI Partners announced that it has completed its acquisition of the Contract Development and Manufacturing Organization (CDMO) and Cell Solutions businesses from Charles River Laboratories International. The combined operations now form Rose BioSolutions (“Rose Bio” for those in the know), a company providing exclusively advanced therapy development and manufacturing. [Read more…]
Press Releases: Press releases are provided by the issuer and may be published by BioInformant as paid content. The issuer is solely responsible for the content and claims contained within these announcements. BioInformant does not independently verify or endorse the claims made by the issuer. For questions about an individual Press Release or to submit one, write us at [email protected].
The Pipeline for iPSC-Derived Cell Therapeutics in 2026
Despite progress involving the use of induced pluripotent stem cells (iPSCs) within disease modeling and drug discovery applications, it will be a long path to achieve the broad-scale use of iPSC-derived cell types in human patients. [Read more…]
NurExone and NanoPass Technologies Ltd. to Collaborate on Integrated Exosome Delivery Approach for Regenerative Eye and Skin Applications
Collaboration to evaluate MicronJet™ with NurExone exosomes across ophthalmic and aesthetic applications in multi-billion-dollar markets
TORONTO and HAIFA, Israel, Sept. 14, 2026 — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a biopharmaceutical company developing exosome-based regenerative therapies, announces that its Israeli subsidiary, NurExone Biologic Ltd., has entered into a Memorandum of Understanding (the “MOU”) with NanoPass Technologies Ltd. (“NanoPass”), a medical device company specializing in precision delivery, to evaluate the integration of NanoPass’s MicronJet™ platform with NurExone’s exosome formulations for eye and skin applications.
Greenstone Biosciences Wins Breakthrough T1D Grant to Model Diabetes Using Patient-Derived iPSCs
Greenstone Biosciences Awarded Breakthrough T1D Grant to Advance Islet Cell Platform
PALO ALTO, Calif. –Greenstone Biosciences has been awarded a Breakthrough T1D Industry Discovery and Development Partnership (IDDP) grant to develop a T1D-derived islet cell platform aimed at understanding and protecting insulin-producing β cells in people with type 1 diabetes. With support from Breakthrough T1D, Greenstone plans to create induced pluripotent stem cells (iPSCs) from a diverse group of T1D patients and develop 3D pancreatic islet organoids, lab-grown structures containing insulin-producing β cells, to examine how these cells respond to inflammation, metabolic stress, and potential protective therapies. [Read more…]
Disrupting the Cell Therapy Market: Nucleus Biologics Brings Transparency, Customization & Control
In recent years, the cell culture company Nucleus Biologics has been at the forefront of market disruption. In this interview with David Sheehan (CEO), we explore how the company has been growing its team, expanding its production capabilities, launching new products, and impressively, rolling out the world’s first online portal for instantaneous custom cGMP cell culture media configuration.
The pace never slows when your mission is to enable lifesaving science! [Read more…]